Danaher Corp

More Details of Danaher Corp Company

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Company Info

Company codeDHR

Company nameDanaher Corp

IPO dateDec 10, 1969

Founded at1986

CEOMr. Rainer M. Blair

Number of employees61000

Security typeOrdinary Share

Fiscal year-endDec 10

Address2200 Pennsylvania Ave NW Ste 800W

CityWASHINGTON

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code20037-1701

Phone12028280850

Websitehttps://www.danaher.com/

Company codeDHR

IPO dateDec 10, 1969

Founded at1986

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Steven M. Rales

Chairman of the Board

43.49M

--

Mr. Mitchell P. Rales

Director

34.93M

-0.58%

Mr. Alan G. Spoon, J.D.

Independent Director

84.94K

-0.46%

Mr. Rainer M. Blair

President, Chief Executive Officer, Director

74.02K

+418.18%

Mr. John T. Schwieters

Independent Director

38.24K

-1.01%

Mr. Brian W. Ellis

Senior Vice President, General Counsel

22.53K

+445.78%

Mr. Daniel A. Raskas, J.D.

Senior Vice President - Corporate Development

16.02K

-22.69%

Dr. Elias A. Zerhouni, M.D.

Independent Director

12.89K

-2.94%

Prof. Raymond C. Stevens, Ph.D.

Independent Director

6.38K

+1.54K%

Dr. Jose-Carlos Gutierrez-Ramos, Ph.D.

Senior Vice President, Chief Science Officer

5.71K

+90.72%

Name

Name/Position

Position

Shareholding

Change

Mr. Steven M. Rales

Chairman of the Board

43.49M

--

Mr. Mitchell P. Rales

Director

34.93M

-0.58%

Mr. Alan G. Spoon, J.D.

Independent Director

84.94K

-0.46%

Mr. Rainer M. Blair

President, Chief Executive Officer, Director

74.02K

+418.18%

Mr. John T. Schwieters

Independent Director

38.24K

-1.01%

Mr. Brian W. Ellis

Senior Vice President, General Counsel

22.53K

+445.78%

Revenue Breakdown

Currency: USDUpdate time: Wed, Apr 2

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

No Data

By RegionUSD

Name

Revenue

Proportion

All Other

11.14B

46.67%

United States

9.93B

41.58%

China

2.81B

11.75%

By Business

By Region

No Data

Shareholder

Update time: 10 hours ago

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

8.31%

Rales (Steven M)

6.08%

Rales (Mitchell P)

4.88%

BlackRock Institutional Trust Company, N.A.

4.10%

State Street Global Advisors (US)

3.83%

Other

72.80%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

8.31%

Rales (Steven M)

6.08%

Rales (Mitchell P)

4.88%

BlackRock Institutional Trust Company, N.A.

4.10%

State Street Global Advisors (US)

3.83%

Other

72.80%

Type

Shareholder

Proportion

Investment Advisor

37.95%

Investment Advisor/Hedge Fund

33.27%

Individual Investor

11.03%

Research Firm

2.48%

Hedge Fund

2.36%

Pension Fund

2.08%

Bank and Trust

2.03%

Sovereign Wealth Fund

1.38%

Family Office

0.36%

Other

7.06%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

3814

667.43M

93.28%

-8.64M

2024Q4

3912

666.25M

93.21%

-12.81M

2024Q3

3803

666.72M

92.18%

-22.04M

2024Q2

3748

676.83M

91.56%

-20.35M

2024Q1

3757

684.50M

92.62%

-9.01M

2023Q4

3766

684.46M

92.71%

-1.58M

2023Q3

3680

678.81M

92.01%

-4.67M

2023Q2

3635

673.50M

91.35%

-658.33K

2023Q1

3602

668.24M

91.66%

-2.23M

2022Q4

3575

666.43M

91.51%

-6.25M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

59.47M

8.31%

+332.85K

+0.56%

Dec 31, 2024

Rales (Steven M)

43.49M

6.08%

+366.00

+0.00%

Mar 01, 2025

Rales (Mitchell P)

34.93M

4.88%

-202.39K

-0.58%

Mar 01, 2025

BlackRock Institutional Trust Company, N.A.

29.32M

4.1%

+350.54K

+1.21%

Dec 31, 2024

State Street Global Advisors (US)

27.38M

3.83%

-95.41K

-0.35%

Dec 31, 2024

Wellington Management Company, LLP

21.32M

2.98%

-1.99M

-8.53%

Dec 31, 2024

Fidelity Management & Research Company LLC

18.77M

2.62%

-3.07M

-14.05%

Dec 31, 2024

T. Rowe Price Associates, Inc.

18.05M

2.52%

-1.50M

-7.69%

Dec 31, 2024

Capital International Investors

17.66M

2.47%

-169.50K

-0.95%

Dec 31, 2024

Geode Capital Management, L.L.C.

13.36M

1.87%

+315.45K

+2.42%

Dec 31, 2024

Related ETFs

Update time: Wed, Apr 2

Name

Proportion

Parnassus Core Select ETF

6.37%

Monarch Blue Chips Core ETF

3.64%

God Bless America ETF

3.11%

Bancreek U.S. Large Cap ETF

3.1%

Macquarie Focused Large Growth ETF

2.64%

Goldman Sachs Future Health Care Equity ETF

2.52%

Proshares Ultra Health Care

2.46%

Health Care Select Sector SPDR Fund

2.46%

iShares U.S. Healthcare ETF

2.39%

Fidelity MSCI Health Care Index ETF

2.17%

Parnassus Core Select ETF

Proportion6.37%

Monarch Blue Chips Core ETF

Proportion3.64%

God Bless America ETF

Proportion3.11%

Bancreek U.S. Large Cap ETF

Proportion3.1%

Macquarie Focused Large Growth ETF

Proportion2.64%

Goldman Sachs Future Health Care Equity ETF

Proportion2.52%

Proshares Ultra Health Care

Proportion2.46%

Health Care Select Sector SPDR Fund

Proportion2.46%

iShares U.S. Healthcare ETF

Proportion2.39%

Fidelity MSCI Health Care Index ETF

Proportion2.17%

Dividend

A total of 3.76B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 20, 2025

DHR.NB Interim Cash Dividend of gross USD 0.32 paid on Apr 25, 2025 going ex on Mar 28, 2025

Mar 28, 2025

Apr 25, 2025

Mar 28, 2025

Dec 10, 2024

DHR.NB Interim Cash Dividend of gross USD 0.27 paid on Jan 31, 2025 going ex on Dec 27, 2024

Dec 27, 2024

Jan 31, 2025

Dec 27, 2024

Sep 10, 2024

DHR.NB Final Cash Dividend of gross USD 0.27 paid on Oct 25, 2024 going ex on Sep 27, 2024

Sep 27, 2024

Oct 25, 2024

Sep 27, 2024

May 07, 2024

DHR.NB Interim Cash Dividend of gross USD 0.27 paid on Jul 26, 2024 going ex on Jun 28, 2024

Jun 28, 2024

Jul 26, 2024

Jun 28, 2024

Feb 21, 2024

DHR.NB Interim Cash Dividend of gross USD 0.27 paid on Apr 26, 2024 going ex on Mar 27, 2024

Mar 28, 2024

Apr 26, 2024

Mar 27, 2024

Dec 05, 2023

DHR.NB Interim Cash Dividend of gross USD 0.24 paid on Jan 26, 2024 going ex on Dec 28, 2023

Dec 29, 2023

Jan 26, 2024

Dec 28, 2023

Sep 13, 2023

DHR.NB Final Cash Dividend of gross USD 0.27 paid on Oct 27, 2023 going ex on Oct 11, 2023

Oct 12, 2023

Oct 27, 2023

Oct 11, 2023

May 09, 2023

DHR.NB Interim Cash Dividend of gross USD 0.27 paid on Jul 28, 2023 going ex on Jun 29, 2023

Jun 30, 2023

Jul 28, 2023

Jun 29, 2023

Feb 22, 2023

DHR.NB Interim Cash Dividend of gross USD 0.27 paid on Apr 28, 2023 going ex on Mar 30, 2023

Mar 31, 2023

Apr 28, 2023

Mar 30, 2023

Dec 06, 2022

DHR.NB Interim Cash Dividend of gross USD 0.25 paid on Jan 27, 2023 going ex on Dec 29, 2022

Dec 30, 2022

Jan 27, 2023

Dec 29, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

197.760USD

Danaher Corp

197.760

Overview

Company